Norethindrone — Progestin-only oral contraceptive. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Norethindrone
Class
Progestin-only oral contraceptive
Mechanism
Suppresses ovulation in about half of users, thickens cervical mucus, blunts LH/FSH peaks and alters the endometrium.
Used for
Prevention of pregnancy
Common side effects
Menstrual irregularity; Headache; Breast tenderness; Nausea; Dizziness
Warnings
Known or suspected pregnancy (contraindicated); Breast carcinoma (contraindicated); Liver tumors or acute liver disease
Interactions
CYP3A4 inducers (reduced efficacy)
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260131 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Primarily suppresses ovulation; possible additional mechanisms include cervical-mucus changes that inhibit sperm penetration and endometrial changes that reduce implantation likelihood.
On both cards: Used for — Prevention of pregnancy · Common side effects — Breast tenderness; Nausea · Interactions — CYP3A4 inducers (reduced efficacy)
Only on the Norgestimate / Ethinyl Estradiol card: Common side effects — Headache / migraine; Abdominal pain; Irregular uterine bleeding · Warnings — Thromboembolic disorders; Liver disease / jaundice; Hypertension
Mechanism: Binds nuclear estrogen receptors; reduces the elevated LH and FSH seen after menopause via negative feedback.
On both cards: Common side effects — Headache; Breast tenderness; Nausea
Only on the Estradiol (transdermal) card: Used for — Moderate-to-severe menopausal vasomotor symptoms; Postmenopausal osteoporosis prevention only after considering non-estrogen options and significant osteoporosis risk · Common side effects — Back pain; Intermenstrual bleeding · Warnings — The label reports stroke/DVT risks with estrogen alone and stroke/DVT/PE/MI risks with studied estrogen-plus-progestin therapy; Gallbladder disease; Undiagnosed abnormal genital bleeding is a contraindication · Interactions — CYP3A4 inducers (rifampin, St. John's wort); CYP3A4 inhibitors (ketoconazole, ritonavir)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera